Anavex Life Sciences (AVXL) Current Deferred Revenue (2021 - 2025)
Anavex Life Sciences (AVXL) posted Current Deferred Revenue of $805000.0 for Q2 2025, down 2.9% sequentially from $829000.0 in Q1 2025, and down 12.21% YoY from $917000.0 in Q2 2024.
Anavex Life Sciences (AVXL) Current Deferred Revenue (2021 - 2025) Analysis & Trends
Anavex Life Sciences has reported Current Deferred Revenue for 5 years, with the latest figure at $805000.0 in Q2 2025.
- Quarterly Current Deferred Revenue fell 12.21% year-over-year to $805000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $805000.0 (down 12.21% YoY) and the FY2024 annual result came in at $842000.0, down 8.18% from the prior year.
- Current Deferred Revenue retreated to $805000.0 in Q2 2025 per AVXL's latest filing, from $829000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $917000.0 in Q3 2023 and troughed at $443831.0 in Q2 2021.
- A 5-year average of $715188.1 and a median of $829000.0 in 2024 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue surged 106.61% in 2023, then fell 12.21% in 2025.
- Over 5 years, Current Deferred Revenue stood at $443831.0 in 2021, then surged by 106.56% to $916763.0 in 2022, then grew by 0.03% to $917000.0 in 2023, then dropped by 9.6% to $829000.0 in 2024, then fell by 2.9% to $805000.0 in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $805000.0, $829000.0, and $829000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 805,000.00 |
| Mar 31, 2025 | 829,000.00 |
| Dec 31, 2024 | 829,000.00 |
| Sep 30, 2024 | 842,000.00 |
| Jun 30, 2024 | 917,000.00 |
| Mar 31, 2024 | 917,000.00 |
| Dec 31, 2023 | 917,000.00 |
| Sep 30, 2023 | 917,000.00 |
| Jun 30, 2023 | 916,763.00 |
| Mar 31, 2023 | 916,763.00 |
| Dec 31, 2022 | 916,763.00 |
| Sep 30, 2022 | 443,831.00 |
| Jun 30, 2022 | 443,831.00 |
| Mar 31, 2022 | 443,831.00 |
| Dec 31, 2021 | 443,831.00 |
| Sep 30, 2021 | 443,831.00 |
| Jun 30, 2021 | 443,831.00 |
| Mar 31, 2021 | 487,111.00 |